Accepted
at 8:39 p.m. Oct, 23, 2023
by
Ahmed7
Bulk Suggestion
Bulk ID:
zarathustra/10.21.23-07:06PM
Author:
zarathustra
Co-authors:
Cameron
Type of change:
Updated content
Rationale for change
per AMBOSS, Nirsevimab is now preferred over Palivizumab (approved by FDA, July 2023)
Source: AMBOSS - https://www.amboss.com/us/knowledge/bronchiolitis/
Before
After
Extra
Extra
Extra
Extra
Text
Infants age < 2 months with bronchiolitis are at high risk of developing {{c1::apnea}} and/or respiratory failure
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Empty field
Sketchy
Empty field
Sketchy 2
Picmonic
Empty field
Pixorize
Empty field
Physeo
Empty field
OME
Additional Resources
One by one
Empty field